Skip to main content
. Author manuscript; available in PMC: 2017 Sep 20.
Published in final edited form as: Nat Med. 2017 Mar 20;23(4):472–482. doi: 10.1038/nm.4310

Figure 4. Inhibition of c-Fos, Dusp1 and BCR-ABL selectively eradicates CML cells.

Figure 4

a. Experimental design for the analysis of DUSP1 and c-FOS inhibitor treatment of patient derived CML CD34+ cells. Primary CML cells from CP4 were transplanted into NOD Scid gammaC−/− mice recipients which transgenically express human IL-3, IL-6 and GM-CSF (NSGS); engraftment was assessed after two weeks after transplantation, engrafted mice were treated for six weeks with drug combinations, and leukemic burden was determined at 4 and 7 weeks after transplantation. b. Percent human leukemic cells in the bone marrow of NSGS mice at week 2 (left) and week 4 (right) of treatment. Data shown are from one of two experiments with similar results (n = 6 mice per group. P values are indicated above the compared bars). c. Percent CFU numbers determined by LTC-IC assay for samples from two CML patients and a normal donor treated with vehicle or the indicated drug combinations. Data shown are mean CFU numbers ± S.D (n = 3; P values are indicated above the compared bars). Individual data points are denoted as empty circles in each bar graphs.